$27.79
1.465.55%
Last update: Nov 4, 6:30 PM
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History
BEAMNASDAQ
Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.
You can purchase shares of Beam Therapeutics (NASDAQ:BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Beam Therapeutics has a consensus price target of $47.95.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $27.5126 last updated November 4, 2026 at 6:30 PM EST.
There are no upcoming dividends for Beam Therapeutics.
Beam Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases....
